We have focused our efforts on the use of lentiviral vectors to transfer genes to the rapamycin-resistant T cells. Using this approach, the majority of T cells in a given culture can be induced to express the new gene. We have also developed animal models to test the in vivo effect of these immuno-gene therapy strategies. Such models incorporate tumors and also evaluate graft-versus-host disease, which remains the main complication after allogeneic hematopoietic stem cell transplantation. To facilitate implementation of this project, we have entered into a cooperative research agreement with Lentigen Corporation to develop clinical protocols focusing on lentiviral delivery of suicide genes. Relevant cancer sites: Non-Hodgkins Lymphoma, Leukemia. Relevant Research Areas: Gene Therapy, Bone Marrow Transplantation, Organ Transplantation Research, Combined Treatment Modalities, Hematology/Lymph.
|Scaife, M; Pacienza, N; Au, B C Y et al. (2013) Engineered human Tmpk fused with truncated cell-surface markers: versatile cell-fate control safety cassettes. Gene Ther 20:24-34|
|Scaife, Matthew D; Neschadim, Anton; Fowler, D H et al. (2009) Novel application of lentiviral vectors towards treatment of graft-versus-host disease. Expert Opin Biol Ther 9:749-61|
|Symes, J C; Siatskas, C; Fowler, D H et al. (2009) Retrovirally transduced murine T lymphocytes expressing FasL mediate effective killing of prostate cancer cells. Cancer Gene Ther 16:439-52|
|Loisel-Meyer, Severine; Felizardo, Tania; Mariotti, Jacopo et al. (2009) Potent induction of B- and T-cell immunity against human carcinoembryonic antigen-expressing tumors in human carcinoembryonic antigen transgenic mice mediated by direct lentivector injection. Mol Cancer Ther 8:692-702|
|Mossoba, Miriam E; Walia, Jagdeep S; Rasaiah, Vanessa I et al. (2008) Tumor protection following vaccination with low doses of lentivirally transduced DCs expressing the self-antigen erbB2. Mol Ther 16:607-17|